Saudi Arabia Dermatological Drugs Market, By Therapy (Acne, Psoriasis, Rosacea, Alopecia, Others), By Type (Prescription, Over the counter (OTC)), By Route of Administration (Topical Administration, Oral Administration, Parenteral Administration), By Drug Class (Corticosteroids, Retinoids, Antibiotics, Antifungals, Calcineurin Inhibitors, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

Saudi Arabia Dermatological Drugs Market was valued at USD 331.45 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.85% through 2030.

The dermatological drugs market in Saudi Arabia is undergoing robust expansion, fueled by heightened consumer awareness about skincare, a growing incidence of dermatological conditions, and significant advancements in therapeutic solutions. Shifting lifestyle patterns, escalating pollution levels, and increasing stress have contributed to a notable rise in conditions such as acne, atopic dermatitis, and psoriasis.

This market is strategically positioned for sustained growth, driven by progressive regulatory support, enhanced healthcare infrastructure, and an evolving distribution landscape. The burgeoning demand for aesthetic dermatology and innovative skincare solutions highlights a shift towards premium and specialized treatments, underscoring a lucrative growth trajectory.

Saudi Arabia's dermatological drugs sector represents a vibrant and evolving market with substantial opportunities. It provides a competitive platform for both domestic and international pharmaceutical players to leverage cutting-edge innovation and meet the sophisticated demands of an increasingly health-conscious population.

Key Report Takeaways

• The prescription segment led in 2024, driven by chronic conditions such as psoriasis, eczema, atopic dermatitis, acne, and rosacea that require supervised treatment. Biologics, immunosuppressants, and systemic therapies are expanding, with stronger formulations available through dermatologists. Rising awareness and early diagnosis are pushing more patients toward prescription care, especially younger groups seeking timely intervention.
• Topical administration is set for rapid growth, supported by frequent use in acne, dermatitis, fungal infections, and psoriasis. Creams, gels, lotions, and sprays allow direct application, better compliance, and limited systemic exposure. Non-invasive use and lower risk of widespread side effects make topical therapy suitable for long-term management.
• Northern and Central regions hold the largest value share, led by Riyadh, Al-Qassim, and Hail. High urban density, stronger purchasing power, and concentration of dermatologists increase uptake of advanced therapies and aesthetic treatments.
• Key players include AbbVie Biopharmaceuticals GmbH, Pfizer Scientific Technical Limited Company, Glaxo Saudi Arabia Limited, Galderma, Amgen Saudi Arabia Limited, Johnson & Johnson Medical Saudi Arabia Limited, Novartis AG, and Eli Lilly and Company.

Key Market Drivers

Rising Prevalence of Dermatological Conditions

The growing burden of skin disorders in Saudi Arabia is a core driver of expansion in the dermatological drugs sector. Increasing cases of acne, psoriasis, eczema, and atopic dermatitis reflect unmet clinical needs and changing patient priorities. Rapid urbanization has raised exposure to pollutants, while high intake of processed and sugary foods worsens inflammatory conditions. The hot, dry climate, intense UV radiation, and hard water further aggravate dryness, rosacea, and sensitivity, strengthening the need for specialized treatment solutions.

Chronic disorders sustain long term therapy demand. Adult atopic dermatitis prevalence ranges from 6%–13% across provinces. Psoriasis affects about 5.33% of the population in the northern region, 3.4% in the southern region, and 1.5% in the eastern region. A systematic review identified leading diagnoses as skin appendage diseases 24.8%, dermatitis 24%, infections 18.5%, pigmentary disorders 16.1%, and papulosquamous disorders 5.3%. Rising consultations in hospitals and private clinics are increasing prescription volumes, particularly for biologics and targeted systemic therapies.

Growing Awareness of Skin Health and Aesthetic Care

Stronger awareness of preventive skincare and aesthetic improvement is reshaping treatment patterns. Digital platforms and social media have improved understanding of early intervention for acne, pigmentation, and other visible concerns. Public campaigns and clinic outreach programs encourage proactive care, increasing professional consultations and prescription uptake. Youth demographics and rising disposable income support spending on premium skincare and advanced cosmetic procedures.

Utilization patterns vary across countries, reflecting cultural and social preferences. Local findings indicate Botox use at 15%, while another Saudi study reported dermal fillers at 43% and rhinoplasty at 42%. In comparison, a Jordanian study showed higher uptake of botulinum toxin and fillers. Non surgical facial aesthetic procedures, including laser therapy, chemical peels, microneedling, and fillers, continue to gain traction. The fusion of pharmaceuticals and cosmetics has strengthened the cosmeceutical segment, widening product portfolios for both local and global brands.

Advancements in Dermatological Treatments and Technologies

Continuous innovation in drug development and delivery systems is enhancing treatment outcomes. Biologic therapies, including monoclonal antibodies and cytokine inhibitors, target specific immune pathways in psoriasis and atopic dermatitis, improving long term control with fewer systemic effects. Improved topical corticosteroids, retinoids, and antifungal agents, along with nano based and liposomal delivery systems, support better absorption and adherence.

Technological progress also supports aesthetic and regenerative dermatology. Laser therapy, radiofrequency treatments, and chemical peels address cosmetic concerns with limited downtime. Botulinum toxin injections and dermal fillers provide non surgical options for facial rejuvenation. Emerging regenerative approaches, including stem cell based therapies, show potential in managing scars, burns, and aging skin. These advances are expanding the scope of medical and cosmetic dermatology, strengthening overall sector growth in Saudi Arabia.

Download Free Sample Report

Key Market Challenges

High Cost of Advanced Dermatological Treatments

One of the most significant barriers to growth in the Saudi Arabia dermatological drugs market is the high cost of advanced treatments, particularly biologics and specialized dermatological drugs. These treatments, often required for chronic skin conditions like psoriasis and atopic dermatitis, tend to be expensive due to their complex production processes and cutting-edge formulations.

High treatment costs may limit access to these advanced drugs for a significant portion of the population, especially in a market where healthcare spending is still growing but not yet fully equitable. Although Saudi Arabia’s healthcare system has seen vast improvements, not all insurance policies cover advanced dermatological therapies, leaving patients to bear the financial burden. This further reduces the market’s reach to lower- and middle-income groups. High costs may delay the adoption of newer treatments, especially among cost-conscious consumers and institutions. In the long run, this can impede the market's potential growth, particularly in underserved areas.

Pharmaceutical companies may need to focus on cost-reduction strategies, such as local production of biologics, pricing strategies tailored to local market conditions, and stronger partnerships with insurance companies to broaden access to these treatments.

Regulatory and Market Access Challenges

Despite improvements in Saudi Arabia’s regulatory environment under Vision 2030, navigating the regulatory and approval processes for dermatological drugs can still be a time-consuming and complex endeavor. Stringent regulations, approval delays, and inconsistent enforcement across various levels of healthcare providers can create obstacles for new drugs entering the market.

Regulatory hurdles can delay the entry of innovative dermatological treatments, particularly in cases where products are imported from international markets. Approval delays lead to missed opportunities for pharmaceutical companies and reduce market competitiveness. Companies looking to enter the Saudi dermatological drugs market need to ensure compliance with local regulations and standards, which can vary in terms of labeling, marketing, and safety requirements. This can be a challenge for international firms looking to introduce new treatments to the Saudi market. Regulatory challenges may prevent the introduction of certain advanced dermatological therapies, limiting the range of available treatments for patients.

Companies must invest in local regulatory expertise and streamline approval processes to ensure timely market entry. Partnerships with local stakeholders, including regulatory bodies and healthcare providers, can also help improve market access.

Key Market Trends

Surge in Demand for Advanced Dermatological Treatments and Biologics

The increasing prevalence of chronic dermatological conditions such as psoriasis, eczema, and atopic dermatitis, combined with the rising demand for specialized treatments, is leading to an expanded role for advanced therapies like biologics. These biologic treatments, which target specific immune pathways, offer patients more effective and long-lasting relief from skin conditions that have traditionally been challenging to treat.

Biologic treatments are increasingly becoming a first-line solution for severe skin conditions, offering patients new hope and more personalized care. This has led to greater investments in biologic drug development, which will continue to increase as pharmaceutical companies target unmet needs in dermatology. As biologics become more widely available and more affordable due to increasing competition and innovations in treatment formulations, their adoption in treating chronic dermatological diseases will rise significantly, fueling demand for dermatological drugs.

Growing Influence of Aesthetic Dermatology and Non-Invasive Procedures

A significant shift is occurring in the Saudi Arabian healthcare market towards aesthetic dermatology, which combines the science of dermatology with cosmetic enhancements. This trend is largely driven by a growing consumer focus on skincare, beauty, and anti-aging solutions. Non-invasive aesthetic procedures like Botox injections, chemical peels, and laser treatments are becoming increasingly popular, supported by their convenience and relatively lower costs compared to traditional surgical alternatives.

Aesthetic dermatology is expanding beyond traditional treatments to include a broader range of solutions, including injectables, skin rejuvenation products, and fillers. Pharmaceutical companies are increasingly developing products specifically for cosmetic applications, which enhances the overall demand for dermatological drugs. Consumers are placing greater emphasis on maintaining youthful appearances, which is pushing the demand for innovative skincare solutions. This has created a lucrative market for dermal fillers, anti-aging formulations, and topical aesthetic treatments that cater to both medical and cosmetic dermatology.

Segmental Insights

Type Insights

Prescription dermatological drugs dominated in Saudi Arabia in 2024 because chronic conditions such as psoriasis, eczema, atopic dermatitis and acne often need physician-supervised therapy that goes beyond over-the-counter options. Biologics, systemic immunomodulators and potent topicals typically require diagnosis, monitoring and follow-up, which keeps demand anchored in prescription channels. For instance, SaudiPedia reports the Wasfaty service had 5,053 participating pharmacies, 2,223 health centers and 238 hospitals across 172 cities and governorates by the end of May 2024, and it had processed about 108.8 million electronic prescriptions, showing how large-scale e-prescribing and pharmacy fulfillment can reinforce prescription-led access for dermatology treatments. Al-Dawaa pharmacies also said it contributed to dispensing more than 40 million prescriptions through the Wasfaty program, signaling how large retail pharmacy networks are scaling prescription dispensing tied to government health pathways.

Route of Administration Insights

Topical administration is poised for rapid growth because creams, gels, lotions and sprays target localized disease, are easy to use at home and generally carry lower systemic risk than oral or injectable options for long-term management. Topicals remain the default starting point for many everyday conditions, and they are often layered with prescription escalation when disease severity rises. For instance, SaudiPedia reports the Wasfaty network included 5,053 pharmacies by the end of May 2024, supporting broad access to prescribed topical dermatology products through community dispensing and refill workflows. This distribution depth supports compliance and continuity of care as patients manage recurring conditions such as dermatitis, acne and fungal infections.

Download Free Sample Report

Regional Insights

Northern & Central region emerged as the dominant in the Saudi Arabia Dermatological Drugs Market in 2024, holding the largest market share in terms of value. The Central and Northern regions house some of the largest urban centers in Saudi Arabia, including Riyadh, the capital city, and other key urban areas such as Al-Qassim and Hail. Riyadh is the largest city in the country, accounting for a significant portion of the population.

As urban centers tend to have higher population densities, the demand for healthcare products including dermatological drugs naturally increases in these regions. The large population in these regions, coupled with high urbanization rates, ensures a continuous and growing demand for dermatological treatments. Urban populations tend to have higher awareness of healthcare needs and are more likely to seek dermatological care for both medical and aesthetic purposes.

The Central and Northern regions, particularly Riyadh, are the economic hubs of the country, with higher disposable incomes and a more affluent consumer base. This results in increased spending on healthcare, including both therapeutic and cosmetic dermatological products. People in these regions are more inclined to invest in advanced skincare treatments and medications for conditions such as acne, psoriasis, and eczema.

The Central and Northern regions benefit from the highest concentration of healthcare professionals and dermatologists. Riyadh, as the capital, is home to numerous leading hospitals, specialized dermatology clinics, and research centers, making it the primary destination for people seeking dermatological treatments. This concentration of specialized care increases the demand for dermatological drugs, as patients with chronic or complex skin conditions are more likely to be treated in these regions.

These regions also have access to cutting-edge dermatological treatments, including biologics, topical therapies, and aesthetic dermatology treatments. With more dermatologists offering advanced care, there is a stronger reliance on prescription-based dermatological drugs, which further boosts market demand. Healthcare facilities in the Northern and Central regions are often well-equipped with the latest medical technologies and offer a range of dermatological treatments.

The advanced infrastructure in these regions supports the introduction of newer dermatological drugs and fosters a high level of patient care, making these regions the key drivers of market growth. The growing awareness of skin health and aesthetics in Saudi Arabia, especially in urban centers like Riyadh, has led to an increase in the demand for cosmetic dermatology.

Patients in the Northern and Central regions are particularly inclined to seek treatments for aging, acne scars, pigmentation, and overall skin rejuvenation. This growing demand for aesthetic dermatology fuels the consumption of topical treatments, injectables, and other dermatological products.

Recent Developments

• In October 2025, Jamjoom Pharma announced a new corporate brand identity and stated it is entering a new phase focused on scale and new product launches across its portfolio (a company update from a major Saudi-based pharma player active in skin-health categories).
• ​In September 2025, Jamjoom Pharma (Saudi Arabia) and the Iraqi Dermatology Society signed an MoU to collaborate on an eczema awareness initiative (“ECZPLORE”), reflecting regional expansion activity around dermatology disease areas.
• ​In April 2025, a Saudi “Ebglyss (Lebrikizumab) Launch KSA” event was announced to introduce healthcare professionals to lebrikizumab’s clinical profile and positioning in atopic dermatitis care pathways.
• ​In June 2024, LEO Pharma highlighted that tralokinumab is marketed outside the US as Adtralza and is approved for use in adults with moderate-to-severe atopic dermatitis in Saudi Arabia (a lifecycle update alongside the 2024 autoinjector development).

Key Market Players

• AbbVieBiopharmaceuticals GmbH
• PfizerScientific Technical Limited Company
• Glaxo Saudi Arabia Limited (GSK)
• Galderma
• Amgen Saudi Arabia Limited
• Johnson & Johnson Medical Saudi Arabia Limited
• Novartis AG
• Eli Lilly and Company

Report Scope:

In this report, the Saudi Arabia Dermatological Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Saudi Arabia Dermatological Drugs Market, By Therapy:

o   Acne

o   Psoriasis

o   Rosacea

o   Alopecia

o   Others

• Saudi Arabia Dermatological Drugs Market, By Type:

o   Prescription

o   Over the counter (OTC)

• Saudi Arabia Dermatological Drugs Market, By Route of Administration:

o   Topical Administration

o   Oral Administration

o   Parenteral Administration

• Saudi Arabia Dermatological Drugs Market, By Drug Class:

o   Corticosteroids

o   Retinoids

o   Antibiotics

o   Antifungals

o   Calcineurin Inhibitors

o   Others

• Saudi Arabia Dermatological Drugs Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Others

• Saudi Arabia Dermatological Drugs Market, By Region:

o   Eastern

o   Western

o   Northern & Central

o   Southern

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Saudi Arabia Dermatological Drugs Market.

Available Customizations:

 Saudi Arabia Dermatological Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).